Targeting the p53 pathway of apoptosis

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• The p53 protein is a critical tumor suppressor involved in apoptosis, cell cycle arrest, and senescence.
• Dysregulation of p53 is implicated in numerous pathological conditions, including cancer, neurodegeneration, and atherosclerosis.
• Targeting cell death pathways, particularly involving p53, shows therapeutic potential in preclinical disease models.

Purpose of the Study:

• To review recent advancements in p53-induced apoptosis in human diseases.
• To discuss the dual nature of targeting p53 and associated controversies.
• To highlight the role of ursodeoxycholic acid (UDCA) in modulating p53 activity and its therapeutic implications.

Main Methods:

• Literature review of p53-mediated apoptosis.
• Analysis of therapeutic strategies targeting p53.
• Examination of the role of microRNAs and transcription-independent functions in p53 pathways.
• Investigation of UDCA's interaction with Mdm-2 and its effect on p53.

Main Results:

• p53 influences apoptosis through transcriptional and non-transcriptional mechanisms, including microRNAs.
• Therapeutic reactivation of p53 is a promising strategy for cancer treatment.
• Chemical inhibition of p53 may benefit diseases with excessive p53 activation.
• Ursodeoxycholic acid (UDCA) emerges as a potential modulator of p53-Mdm-2 interactions.

Conclusions:

• Targeting p53 presents a "double-edged sword" with potential benefits and risks across various diseases.
• UDCA shows promise as a therapeutic agent for modulating p53 in conditions like cholestatic liver disease.
• Further research into p53-targeted therapies and UDCA's role is warranted for clinical applications.